Melinda Gooderham, MSc, MD, FRCPC: JAK Inhibitors for Psoriasis

Dr. Gooderham reviews the evolving role of JAK inhibitors in the treatment of Psoriasis, focusing on how different mechanisms of JAK inhibition may influence therapeutic effects. Her presentation compares competitive inhibition and allosteric inhibition, explaining the distinctions between these approaches and their potential relevance in psoriasis management.

Topics Covered

The role of JAK inhibition in psoriasis treatment
Mechanisms of action of JAK inhibitors
Differences between competitive and allosteric JAK inhibition
How varying mechanisms may influence treatment strategies
Emerging perspectives on targeted immune modulation in psoriasis

Explore Related Resources

MORE COVERAGE FROM THE 2025 AAD ANNUAL MEETING

Peter Lio, MD: Updates in AD and Diet

Dr. Lio discusses the complex relationship between diet and atopic dermatitis, addressing common patient questions, misconceptions, and concerns regarding dietary modifications. His presentation emphasizes the

Emmy Graber, MD: New Efficacy Evidence for Acne and Rosacea Devices

Dr. Graber reviews emerging evidence supporting the use of energy-based devices for the treatment of Acne Vulgaris and Rosacea, highlighting how advances in laser and

Steve Daveluy, MD: Using Cryoinsufflation in Patients with Hidradenitis Suppurativa

Dr. Daveluy discusses practical techniques and clinical considerations for using cryoinsufflation in the treatment of Hidradenitis Suppurativa (HS). His presentation provides guidance on incorporating this

Christopher Bunick, MD, PhD: Clearing Up Questions Around Benzene in Benzoyl Peroxide Products

Dr. Bunick examines the ongoing discussion surrounding benzene contamination concerns in benzoyl peroxide (BPO) products, addressing questions about product safety, regulatory oversight, and best practices

Christopher Bunick, MD, PhD: Antibiotic Update for Acne and Rosacea

Dr. Bunick provides a comprehensive review of the evolving role of antibiotics in treating Acne Vulgaris and Rosacea, examining current evidence on their benefits, limitations,

Lisa Swanson, MD: What’s New in Pediatric Dermatology at AAD 2025

Dr. Swanson highlights key developments presented at the AAD 2025 Annual Meeting, providing an overview of emerging therapies, clinical research, and treatment advances across several

Peter Lio, MD: Managing Itch in Patients with Cancer

Dr. Lio discusses strategies for addressing chronic itch (pruritus) in patients undergoing treatment for non-dermatologic cancers, a symptom that can significantly affect comfort, sleep quality,

Steve Daveluy, MD: Pharm to Table: How Medications and Diet Interact

Dr. Daveluy explores the important relationship between nutrition and dermatologic therapies, discussing how dietary choices can influence the effectiveness, absorption, and side effect profiles of

Jennifer Hsiao, MD: Recalcitrant Hidradenitis Suppurativa—What to do Next?

Dr. Jennifer Hsiao shares emerging strategies for treating recalcitrant hidradenitis suppurativa when standard therapies fail. Topics Covered: Management of treatment-resistant HS Emerging therapies and clinical

Raj Chovatiya, MD, PhD: Chronic Hand Eczema at AAD 2025

Dr. Chovatiya highlights key insights from a symposium presented at the AAD 2025 Annual Meeting, focusing on the diagnosis and management of **Chronic Hand Eczema

David Rosmarin, MD: How to Use Ruxolitinib Cream for Vitiligo

Drawing from his presentation at the AAD 2025 Annual Meeting, Dr. Rosmarin reviews practical strategies for maximizing treatment outcomes with Ruxolitinib> cream in patients with

Iltefat Hamzavi, MD: Surgical Options for Vitiligo

Dr. Hamzavi reviews the role of surgical intervention in the management of Vitiligo, focusing on identifying appropriate candidates and outlining the available procedural techniques for

Iltefat Hamzavi, MD: Carbon Dioxide Laser for Hidradenitis Suppurativa

Dr. Hamzavi reviews key takeaways from his presentation during the AAD 2025 Annual Meeting session on surgical management of **Hidradenitis Suppurativa (HS). His discussion focuses

Aaron Drucker MD, SCM, FRCPC: A Network Meta-analysis of Systemic Therapies for Atopic Dermatitis

Drawing from his presentation at the AAD 2025 Annual Meeting, Dr. Drucker reviews findings from a network meta-analysis comparing systemic therapies for Atopic Dermatitis. His

Raj Chovatiya, MD, PhD: Social and Structural Disease-State Disparities in Inflammatory Skin Disease in Skin of Color

In this recap of his presentation at the AAD 2025 Annual Meeting, Dr. Chovatiya examines the social and structural disparities that influence the diagnosis, treatment,

Julien Seneschal, MD, PhD: Immune Pathogenesis of Vitiligo

Drawing from his presentation at the AAD 2025 Annual Meeting, Dr. Seneschal reviews the immune mechanisms underlying Vitiligo and explains why long-term maintenance therapy is

The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.

The content of the 2025 AAD Annual Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Annual Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.

JCAD Archives